Open AccessUse of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India
Author(s) -
Julie Sachdeva,
Karthik Vinay Mahesh,
Ritu Shree,
Gaurav Jain,
Aastha Takkar Kapila,
Tirulapati Padmavathi Shashikala,
Manoj Goyal,
Manish Modi,
Vivek Lal
Publication year - 2020
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/ijp.ijp_333_18
Subject(s) - rituximab , myasthenia gravis , refractory (planetary science) , medicine , antibody , gastroenterology , observational study , immunology , biology , astrobiology
Approximately 10%-15% of patients with myasthenia gravis (MG) are refractory to standard treatment. A sizable chunk of these patients is due to muscle-specific tyrosine kinase (MuSK) antibody-positive MG which often runs a severe course with frequent relapses and poor response to conventional treatment. We report six patients with refractory MuSK-positive MG who responded well to the treatment with rituximab.